Pharma Stability: Insights, Guidelines, and Expertise
ICH Q1A (R2) provides recommendations on the type of stability data required to support marketing applications for pharmaceuticals. It defines acceptable test conditions, duration, frequency of testing, packaging considerations, and number of batches.
Click to read the full article.
Available from Pharma SOP:
Click to read the full article.
Available from Pharma SOP:
Click to read the full article.
Each pull point should include:
Click to read the full article.
Biologic products are particularly sensitive to manufacturing and environmental variations. Even minor changes in formulation, scale, or equipment can affect stability. Stability testing during tech transfer ensures:
Click to read the full article.
Adaptive stability testing involves adjusting the study design, sampling frequency, or analytical focus in response to data trends, formulation behavior, or regulatory needs. It aligns with the principles of Quality by Design (QbD) and risk-based development by allowing greater flexibility while preserving scientific rigor.
Click to read the full article.
Available from Pharma SOP:
Click to read the full article.
Available from Pharma SOP:
Click to read the full article.
CCI refers to the ability of the primary packaging system to prevent ingress of contaminants and egress of product components under intended storage conditions. It is essential for maintaining sterility, potency, and physical integrity throughout the shelf life.
Click to read the full article.
LBFs provide advantages such as enhanced bioavailability, solubility, and lymphatic absorption. However, they are prone to degradation via:
Click to read the full article.